Ignite Creation Date:
2024-05-19 @ 5:33 PM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06412471
Status:
RECRUITING
Last Update Posted:
2024-05-14
First Post:
2024-04-26
Brief Title:
A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients
Sponsor:
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
Organization:
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
Study Overview
Official Title:
A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study includes two parts part A is for non-squamous NSCLC and part B is for squamous NSCLC
Detailed Description:
This study is a study of SSGJ-707 combination therapy in First-line advanced NSCLC Patients This study includes two parts part A is for non-squamous NSCLC and part B is for squamous NSCLC Each part will assess the efficacy and safety of the preset several dose levels of SSGJ-707 in advanced NSCLC Patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None